Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2014

01.05.2014 | Maternal-Fetal Medicine

Do uterotonic drugs increase risk of abruptio placentae and eclampsia?

verfasst von: Mamoru Morikawa, Kazutoshi Cho, Takahiro Yamada, Takashi Yamada, Shoji Sato, Hisanori Minakami

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether the use of uterotonics, including oxytocin and prostaglandins, increases the risk of abruptio placentae and eclampsia.

Materials and methods

A retrospective analysis was conducted among 260,174 Japanese women at term. Demographic characteristics were studied as possible candidates for risk factors of abruptio placentae and eclampsia using multivariate logistic regression analyses.

Results

A total of 1,058 (0.41 %) and 147 (0.06 %) women developed abruptio placentae and eclampsia, respectively. Abruptio placentae and eclampsia occurred in 177 (0.29 %) and 42 (0.07 %) of the 61,857 women treated with uterotonics, respectively. Multivariate regression analyses indicated that uterotonics did not increase risk of developing either abruptio placentae or eclampsia. Primiparity [odds ratio (95 % confidence interval) 1.41 (1.24–1.60)], age ≥35 years [1.17 (1.03–1.33)], and presence of hypertension [2.42 (1.93–3.03)] were significant independent risk factors for abruptio placentae, while advancing gestation [0.67 (0.63–0.71)] decreased risk of abruptio placentae. Primiparity [odds ratio (95 % confidence interval) 4.06 (2.49–6.63)], age <20 years [2.44 (1.07–5.58)], presence of hypertension [28.7 (20.5–40.1)], and advancing gestation [1.28 (1.11–1.47)] were significant independent risk factors for eclampsia.

Conclusion

The use of uterotonics did not increase the risk of abruptio placentae and eclampsia.
Literatur
1.
Zurück zum Zitat Pharmaceutical and Food Safety Bureau, Japanese Ministry of Labour, Health and Welfare (2010) Concerning revision of package insert (file number 0601-1) Pharmaceutical and Food Safety Bureau, Japanese Ministry of Labour, Health and Welfare (2010) Concerning revision of package insert (file number 0601-1)
2.
Zurück zum Zitat Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ, UK Obstetric Surveillance System (2010) Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol 115:910–917PubMedCrossRef Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ, UK Obstetric Surveillance System (2010) Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol 115:910–917PubMedCrossRef
3.
Zurück zum Zitat Roberts CL, Algert CS, Knight M, Morris JM (2010) Amniotic fluid embolism in an Australian population-based cohort. BJOG 117:1417–1421PubMedCrossRef Roberts CL, Algert CS, Knight M, Morris JM (2010) Amniotic fluid embolism in an Australian population-based cohort. BJOG 117:1417–1421PubMedCrossRef
4.
Zurück zum Zitat Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J, Roberts CL, Spong C, Sullivan E, van Roosmalen J, Zwart J (2012) Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. doi:10.1186/1471-2393-12-7 PubMedCentralPubMed Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J, Roberts CL, Spong C, Sullivan E, van Roosmalen J, Zwart J (2012) Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. doi:10.​1186/​1471-2393-12-7 PubMedCentralPubMed
5.
Zurück zum Zitat Yamada T, Yamada T, Morikawa M, Takeda M, Akaishi R, Nishida R, Araki N, Koyama T, Minakami H (2011) Do uterotrophic drugs increase the risk of fatal hemorrhagic brain stroke? J Perinat Med 39:23–26PubMedCrossRef Yamada T, Yamada T, Morikawa M, Takeda M, Akaishi R, Nishida R, Araki N, Koyama T, Minakami H (2011) Do uterotrophic drugs increase the risk of fatal hemorrhagic brain stroke? J Perinat Med 39:23–26PubMedCrossRef
6.
Zurück zum Zitat Fontenot MT, Lewis DF, Barton CB, Jones EM, Moore JA, Evans AT (2005) Abruptio placentae associated with misoprostol use in women with preeclampsia. J Reprod Med 50:653–658PubMed Fontenot MT, Lewis DF, Barton CB, Jones EM, Moore JA, Evans AT (2005) Abruptio placentae associated with misoprostol use in women with preeclampsia. J Reprod Med 50:653–658PubMed
7.
Zurück zum Zitat Martinez de Tejada B, Martillotti G, Lapaire O, Hoesli I, Irion O (2010) The risk of placental abruption when using prostaglandins for cervical ripening in women with preeclampsia: comparing misoprostol versus dinoprostone. J Matern Fetal Neonatal Med 23:988–993PubMedCrossRef Martinez de Tejada B, Martillotti G, Lapaire O, Hoesli I, Irion O (2010) The risk of placental abruption when using prostaglandins for cervical ripening in women with preeclampsia: comparing misoprostol versus dinoprostone. J Matern Fetal Neonatal Med 23:988–993PubMedCrossRef
8.
Zurück zum Zitat Minakami H, Hiramatsu Y, Koresawa M et al (2011) Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2011 edition. J Obstet Gynaecol Res 37:1174–1197PubMedCrossRef Minakami H, Hiramatsu Y, Koresawa M et al (2011) Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2011 edition. J Obstet Gynaecol Res 37:1174–1197PubMedCrossRef
9.
Zurück zum Zitat Morikawa M, Cho K, Yamada T, Yamada T, Sato S, Minakami H (2012) Risk factors for eclampsia in Japan between 2005 and 2009. Int J Gynaecol Obstet 117:66–68PubMedCrossRef Morikawa M, Cho K, Yamada T, Yamada T, Sato S, Minakami H (2012) Risk factors for eclampsia in Japan between 2005 and 2009. Int J Gynaecol Obstet 117:66–68PubMedCrossRef
10.
Zurück zum Zitat Matsuda Y, Hayashi K, Shiozaki A, Kawamichi Y, Sato S, Saito S (2011) Comparison of risk factors for placental abruption and placenta previa: case–cohort study. J Obstet Gynaecol Res 37:538–556PubMedCrossRef Matsuda Y, Hayashi K, Shiozaki A, Kawamichi Y, Sato S, Saito S (2011) Comparison of risk factors for placental abruption and placenta previa: case–cohort study. J Obstet Gynaecol Res 37:538–556PubMedCrossRef
11.
Zurück zum Zitat Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG; HYPITAT study group (2009) Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 374:979–988 Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG; HYPITAT study group (2009) Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 374:979–988
12.
Zurück zum Zitat Minakami H, Kubo T, Takeda S, Kawabata M, Kobayashi T, Nakabayashi M (2009) Placental abruption, HELLP syndrome, and eclampsia in Japan. Nippon Sanka-Fujinka Gakkai Zasshi 61:1559–1567 (in Japanese) Minakami H, Kubo T, Takeda S, Kawabata M, Kobayashi T, Nakabayashi M (2009) Placental abruption, HELLP syndrome, and eclampsia in Japan. Nippon Sanka-Fujinka Gakkai Zasshi 61:1559–1567 (in Japanese)
13.
Zurück zum Zitat Sheiner E, Shoham-Vardi I, Hadar A, Hallak M, Hackmon R, Mazor M (2002) Incidence, obstetric risk factors and pregnancy outcome of preterm placental abruption: a retrospective analysis. J Matern Fetal Neonatal Med 11:34–39PubMedCrossRef Sheiner E, Shoham-Vardi I, Hadar A, Hallak M, Hackmon R, Mazor M (2002) Incidence, obstetric risk factors and pregnancy outcome of preterm placental abruption: a retrospective analysis. J Matern Fetal Neonatal Med 11:34–39PubMedCrossRef
14.
Zurück zum Zitat Sheiner E, Shoham-Vardi I, Hallak M, Hadar A, Gortzak-Uzan L, Katz M, Mazor M (2003) Placental abruption in term pregnancies: clinical significance and obstetric risk factors. J Matern Fetal Neonatal Med 13:45–49PubMedCrossRef Sheiner E, Shoham-Vardi I, Hallak M, Hadar A, Gortzak-Uzan L, Katz M, Mazor M (2003) Placental abruption in term pregnancies: clinical significance and obstetric risk factors. J Matern Fetal Neonatal Med 13:45–49PubMedCrossRef
15.
17.
Zurück zum Zitat Knight M; UKOSS (2007) Eclampsia in the United Kingdom 2005. BJOG 114:1072–1078 Knight M; UKOSS (2007) Eclampsia in the United Kingdom 2005. BJOG 114:1072–1078
18.
Zurück zum Zitat van der Tuuk K, Koopmans C, Groen H, Mol BW, van Pampus MG; HYPITAT study group (2011) Impact of the HYPITAT trial on doctors’ behaviour and prevalence of eclampsia in the Netherlands. BJOG 118:1658–1660 van der Tuuk K, Koopmans C, Groen H, Mol BW, van Pampus MG; HYPITAT study group (2011) Impact of the HYPITAT trial on doctors’ behaviour and prevalence of eclampsia in the Netherlands. BJOG 118:1658–1660
19.
Zurück zum Zitat Jozwiak M, Oude Rengerink K, Benthem M, van Beek E, Dijksterhuis MG, de Graaf IM, van Huizen ME, Oudijk MA, Papatsonis DN, Perquin DA, Porath M, van der Post JA, Rijnders RJ, Scheepers HC, Spaanderman ME, van Pampus MG, de Leeuw JW, Mol BW, Bloemenkamp KW; PROBAAT Study Group (2011) Foley catheter versus vaginal prostaglandin E2 gel for induction of labour at term (PROBAAT trial): an open-label, randomised controlled trial. Lancet 378:2095–2103 Jozwiak M, Oude Rengerink K, Benthem M, van Beek E, Dijksterhuis MG, de Graaf IM, van Huizen ME, Oudijk MA, Papatsonis DN, Perquin DA, Porath M, van der Post JA, Rijnders RJ, Scheepers HC, Spaanderman ME, van Pampus MG, de Leeuw JW, Mol BW, Bloemenkamp KW; PROBAAT Study Group (2011) Foley catheter versus vaginal prostaglandin E2 gel for induction of labour at term (PROBAAT trial): an open-label, randomised controlled trial. Lancet 378:2095–2103
Metadaten
Titel
Do uterotonic drugs increase risk of abruptio placentae and eclampsia?
verfasst von
Mamoru Morikawa
Kazutoshi Cho
Takahiro Yamada
Takashi Yamada
Shoji Sato
Hisanori Minakami
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2014
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-3101-8

Weitere Artikel der Ausgabe 5/2014

Archives of Gynecology and Obstetrics 5/2014 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.